Meet the Executive Leading Investment Strategy at UPMC Enterprises

Fabian Tenenbaum joins as an executive vice president with significant experience growing startup companies in health care.

With more than two decades of experience building biopharma and medical device companies from early academic discovery through commercialization, Fabian Tenenbaum brings a deeply operational perspective to innovation in health care.

His career has spanned company formation, capital strategy, clinical development, and scaling organizations across biotechnology, therapeutics, and medical technologies. He now brings that experience to his work as executive vice president at UPMC Enterprises.

Fabian was drawn to UPMC Enterprises by its leadership, innovation infrastructure, and differentiated portfolio of companies. His advisory work evolved into hands-on collaboration, through which he developed close ties with the UPMC Enterprises team.

“As I got to know the team, the portfolio, and more people across the UPMC system, it became clear how differentiated UPMC Enterprises truly is,” he said. “It brings together investment, ideation, and strategic thinking around health care — anchored by a patient-first mindset and amplified by the scale and capabilities of the UPMC system. I see immense long-term value in this model.”

We sat down with Fabian to discuss his goals for UPMC Enterprises, its portfolio, and the opportunities ahead.

What career experience will you draw on in your role at UPMC Enterprises?

Over the past 20 years, I’ve built biopharma and medical device companies from early ideation and academic science into successful organizations. That work has included company formation, capital raising, advancing programs through clinical development and commercialization, and guiding companies through financing stages ranging from seed and private rounds to public markets and strategic transactions.

What I bring to Enterprises is an operator’s perspective — experience building companies from early scientific concepts through financing, clinical development, strategic partnerships, and commercialization. I believe that practical experience can help strengthen how we evaluate, build, and scale platforms across the portfolio.

What excites you about UPMC’s innovation ecosystem, and where do you see the greatest opportunity to make an impact?

What excites me most is the breadth and depth of expertise across therapeutic areas at UPMC, which is an incredibly differentiated asset. I’ve already had the opportunity to work with exceptional clinicians such as Dr. José-Alain Sahel, Dr. David Okonkwo, and Dr. Joel Nelson and see the vision and expertise they each bring to advancing patient care.

UPMC Enterprises has a distinct ability to combine deep clinical insight with system-level understanding to identify where health care needs are today — and where they are heading in the future. That combination becomes even more powerful through collaboration with leading institutions such as the University of Pittsburgh and Carnegie Mellon University.

The field is evolving rapidly, particularly at the intersection of computational biology, AI, clinical data, and care delivery. These technologies are reshaping how we discover therapies, identify novel biological targets, optimize operations, and personalize treatment decisions. UPMC Enterprises is well positioned to help translate these capabilities into scalable solutions that improve outcomes while reducing system complexity and cost.

We are aware of and closely watching industry trends such as accelerating drug development, enabling precision medicine, improving diagnostics, and advancing operational efficiency. Many of these capabilities already exist within our portfolio, and there is a significant opportunity to further accelerate their impact.

Beyond expertise, UPMC also has exceptional longitudinal clinical and operational data resources that can help drive these initiatives. Our real-world data platform, Ahavi, is a strong example of how de-identified longitudinal data can support software development, clinical insights, and new diagnostic and therapeutic approaches through both retrospective and prospective analysis.

How will you support continued collaboration between UPMC Enterprises and experts across UPMC?

A core strength of UPMC Enterprises is its close connection to the broader UPMC health system. That alignment helps ensure we are innovating in ways that directly address real clinical and operational needs. At the center of this is our ability to build strong relationships and stay closely connected to the teams working on the frontlines of care delivery.

Maintaining deep engagement with UPMC clinicians and leaders is essential to identifying meaningful needs and translating them into impactful innovation. I plan to continue collaborating with UPMC colleagues through medical thought leadership, centers of excellence, and ongoing dialogue with physicians who are advancing treatment and caring for patients every day. These relationships help us identify opportunities to introduce new technologies, platforms, and best practices that can improve care delivery and patient outcomes.

There is also significant value in being part of an integrated delivery and finance network to better understand value-based care, system-wide economics, and how to improve outcomes while bending the cost curve over time. That perspective is critical when evaluating solutions that can create long-term value for all stakeholders.

My goal is to continue deepening and expanding those relationships across the organization.

How do you see Enterprises further advancing life sciences and digital health from research and commercialization to clinical application?

There are several ways we can approach this, and much of it has informed how the team continues to evolve. A strong example is the group I’m leading, which focuses on identifying emerging trends and breakthrough technologies both internally and externally. The team works closely with scientists and clinicians across the system to evaluate opportunities, understand their long-term potential, and determine how they fit into the future of health care.

From there, the focus becomes helping incubate and translate those ideas from early-stage concepts into commercially viable platforms and companies. That requires understanding the translational, operational, clinical, and strategic steps needed to move an innovation from an academic environment toward real-world application.

UPMC Enterprises brings significant experience and resources to this process, with dedicated teams focused on commercialization, company creation, and accelerating assets toward market adoption. Equally important is maintaining discipline around where we deploy time and capital so we focus on opportunities with the greatest potential to create long-term patient and strategic value.

Next Steps

• Learn more about the full leadership team at UPMC Enterprises.
• Read a profile of José-Alain Sahel, MD, a global leader in ophthalmology care, research, and commercialization.